This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 12496 results found since Jan 2013.
Pronounced State Level Disparities in Medicaid Prescribing of Buprenorphine for Opioid Use Disorder (2019-2020)
CONCLUSIONS: The COVID-19 pandemic exacerbated state-level disparities in buprenorphine prescribing for OUD among Medicaid patients. Legislation expanding buprenorphine waivered providers and Medicaid expansion may have contributed to the statistically significant changes in state buprenorphine prescriptions.PMID:37650858 | DOI:10.15288/jsad.22-00373
Source: Journal of Studies on Alcohol and Drugs - August 31, 2023 Category: Addiction Authors: Sydney R Dana Stephanie D Nichols Kenneth L McCall Brian J Piper Source Type: research
BUPRENORPHINE AND NALOXONE tablet Actavis Pharma, Inc.
Updated Date: Thu, 31 Aug 2023 00:00:00 EDT
Source: DailyMed Drug Label Updates - August 31, 2023 Category: Drugs & Pharmacology Source Type: alerts
Survey of barriers and opportunities for prescribing buprenorphine for opioid use disorder in Alabama
.
Source: Journal of Addictive Diseases - August 31, 2023 Category: Addiction Authors: Ishika Patel Li Li Haelim Jeong Justin T. McDaniel Shanna McIntosh Ellen Robertson David L. Albright Source Type: research
The experience of buprenorphine implant in patients with opioid use disorder: a series of narrative interviews
ConclusionsThis study illustrates the complex problems of living with OUD and provides insights into the added value of an innovative buprenorphine implant therapy that, due to its administration route and prolonged duration, allows patients to take an additional step toward total opioid abstinence and complete recovery of daily life.
Source: Frontiers in Psychiatry - August 31, 2023 Category: Psychiatry Source Type: research
